Entia Biosciences, Inc.
ERGO
$0.0001
-$0.0001-50.00%
| 12/31/2016 | 09/30/2016 | 06/30/2016 | 03/31/2016 | 12/31/2015 | |
|---|---|---|---|---|---|
| Net Income | 38.24% | 52.19% | 52.67% | 11.82% | 1.59% |
| Total Depreciation and Amortization | -45.00% | 214.93% | -33.24% | -24.59% | -15.79% |
| Total Amortization of Deferred Charges | -81.35% | -80.59% | -89.34% | -66.82% | -37.68% |
| Total Other Non-Cash Items | -78.60% | -98.43% | -93.35% | -19.98% | -6.93% |
| Change in Net Operating Assets | -41.83% | 24.93% | 1.22% | -5.64% | 43.25% |
| Cash from Operations | -33.27% | 55.71% | 41.70% | -13.12% | 21.12% |
| Capital Expenditure | -- | 100.00% | 79.76% | -72.34% | -72.34% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 46.21% | 69.84% | 73.41% | 78.49% | 67.73% |
| Cash from Investing | 66.67% | 77.18% | 74.41% | 64.11% | 53.08% |
| Total Debt Issued | 729.40% | 167.15% | -24.26% | -74.31% | -83.51% |
| Total Debt Repaid | 68.94% | 71.59% | 74.37% | -39.41% | -113.84% |
| Issuance of Common Stock | -- | -100.00% | -94.60% | 53.29% | 111.40% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 60.46% | -59.30% | -70.93% | -37.37% | -38.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 169.06% | 11.31% | -198.56% | -214.81% | -220.29% |
